Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Basilea's novel antibiotic BAL30072 is effective against multidrug-resistant Gram-negative bacteria that express the New Delhi metallo- beta-lactamase 1 (NDM-1) resistance factor, according to new research data.
Subscribe to our email newsletter
BAL30072 is a novel siderophore (iron-binding) sulfactam antibiotic conferring potent bactericidal activity against Gram-negative pathogens.
NDM-1 is an enzyme that leads to resistance towards antibiotics that have been the mainstay of treatment of clinically important pathogens such as Escherichia coli or Klebsiella pneumoniae.
BAL30072 phase I clinical testing in-vitro data presented at ECCMID/ICC has shown that it is resistant to degradation by NDM-1 and is active against many of the highly resistant isolates tested while standard anti-Gram-negative antibiotics such as meropenem, ceftazidime or aztreonam covered only a minority of the strains.
BAL30072 and meropenem, when combined, enhanced activity and resulted in inhibition of more than 90% of the isolates.
BAL30072 was tested alongside reference drugs currently used for the treatment of Acinetobacter infections and showed greater activity than all the marketed beta-lactam antibiotics as well as most of the other comparators.